Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Circulating anticoagulant associated with chronic active hepatitis

W M Zinn, D Y Graham, N P Grose

    Southern Medical Journal
    |October 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Quantitation of Helicobacter pylori in the stomach using quantitative polymerase chain reaction assays.

    Helicobacter·2000
    Same author

    Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer.

    The American journal of pathology·2000
    Same author

    Helicobacter pylori and gastric cancer: both primary and secondary preventive measures are required.

    Archives of internal medicine·2000
    Same author

    Proinflammatory activation of neutrophils and monocytes by Helicobacter pylori is not associated with cagA, vacA or picB genotypes.

    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2000
    Same author

    Modified Genta triple stain for identifying Helicobacter pylori.

    Journal of clinical pathology·2000
    Same author

    Furazolidone combination therapies for Helicobacter pylori infection in the United States.

    Alimentary pharmacology & therapeutics·2000

    Patients with chronic active hepatitis may develop circulating anticoagulants targeting factors XI and XII. This finding necessitates caution and consideration of bleeding risks, especially before invasive procedures like liver biopsy.

    Area of Science:

    • Hepatology
    • Hematology
    • Immunology

    Background:

    • Chronic active hepatitis often presents with diverse serologic abnormalities.
    • Understanding these abnormalities is crucial for patient management and risk assessment.

    Observation:

    • A case of chronic active hepatitis is presented in a patient with a circulating anticoagulant.
    • This anticoagulant specifically targets coagulation factors XI and XII.

    Findings:

    • The presence of circulating anticoagulants should be suspected in chronic active hepatitis patients exhibiting a prolonged partial thromboplastin time.
    • This specific anticoagulant complication is associated with factors XI and XII.

    Implications:

    • The risk associated with liver biopsy in these patients remains uncharacterized.

    Related Experiment Videos

  • Healthcare providers must consider this potential bleeding hazard in all chronic active hepatitis patients, particularly those with prolonged partial thromboplastin time.